Literature DB >> 3168145

Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.

P A Philip1, L D Lewis, C A James, H J Rogers.   

Abstract

Ifosfamide (IF) pharmacokinetics and the plasma (NBP)-alkylating activity were determined in 33 patients with different tumours after the administration of IF as single-agent chemotherapy. All subjects had been phenotyped for debrisoquine oxidation. There is a lack of correlation between the debrisoquine metabolic ratio (DMR) and either the total plasma clearance of IF (CLIF) or the AUC of the plasma NBP-alkylating activity.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3168145     DOI： 10.1007/bf00254239

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  21 in total

1.  Pharmacokinetics of ifosfamide.

Authors:  L M Allen; P J Creaven
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.

Authors:  D L Hill; W R Laster; M C Kirk; S el-Dareer; R F Struck
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

3.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

4.  Rapid gas chromatographic determination of ifosfamide in biological fluids.

Authors:  M R Talha; H J Rogers
Journal:  J Chromatogr       Date:  1984-11-09

Review 5.  The comparative pharmacology of cyclophosphamide and ifosfamide.

Authors:  M Colvin
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

Review 6.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 7.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 8.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 9.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

10.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908
View more
  3 in total

1.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

Review 2.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

Review 3.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.